The mechanism of luteolin suppressing pancreatic cancer (PC) via cyclin B1 (CCNB1)-mediated signalling
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-27 03:55
摘要：
Luteolin effectively suppresses pancreatic cancer growth by targeting cyclin B1 (CCNB1), leading to cell cycle arrest and apoptosis. The study utilized various assays, including patient-derived organoids and xenograft models, to demonstrate luteolin's potential as a therapeutic agent. By disrupting the CCNB1/CDK1 complex, luteolin induces significant anti-tumor effects, highlighting its promise in addressing the challenges of pancreatic cancer treatment.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
0.5分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.5分
technical_barrier_competition
0.5分
关键证据
Luteolin significantly inhibited the migration and proliferation of pancreatic cancer (PC) cells.
The study identified CCNB1 as a pivotal target, leading to cell cycle arrest and reduced tumor progression.
In vivo, luteolin effectively inhibited subcutaneous tumor growth in a xenograft mouse model.
真实性检查
否
AI评分总结
Luteolin effectively suppresses pancreatic cancer growth by targeting cyclin B1 (CCNB1), leading to cell cycle arrest and apoptosis. The study utilized various assays, including patient-derived organoids and xenograft models, to demonstrate luteolin's potential as a therapeutic agent. By disrupting the CCNB1/CDK1 complex, luteolin induces significant anti-tumor effects, highlighting its promise in addressing the challenges of pancreatic cancer treatment.